Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors — US NIS Cabo

Locally Advanced or Metastatic Renal Cell Carcinoma Clinical Trial

Official title:
Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Status Completed

Clinical Trial Summary

To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor (CPI) treatment (a type of immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells) in US community oncology practices will be analyzed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Renal Cell
Locally Advanced or Metastatic Renal Cell Carcinoma

Clinical Trial Details

NCT number	NCT04353765
Study type	Observational
Source	Ipsen
Contact
Status	Completed
Phase
Start date	January 30, 2020
Completion date	June 5, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03945773` - Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors	Phase 2